Pharmafile Logo
Pharmafocus logo
Advanced Search

4D Molecular Therapeutics

Showing 1 posts of 1 posts found.

eye2

Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023
Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …

News
The Gateway to Local Adoption Series

Latest content

MedPharm appoints Jason Mieding as chief operating officer

November 8, 2026

UKRI backs five hubs developing AI tools for earlier disease detection

November 8, 2026

Coriolis Pharma appoints Teun van der Heide as CEO

November 7, 2026

NEC joins €6.5m European project using AI for pandemic vaccine design

November 6, 2026

The evidence bar impacting UK medical cannabis access

November 6, 2026